Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels

Journal of Pain and Symptom Management

Volumn 46, Issue 1, 2013, Pages 65-75

  Kapil, Ram P ^a   Cipriano, Alessandra ^a   Friedman, Kristen ^a   Michels, Gregory ^a   Shet, Manjunath S ^a   Colucci, Salvatore V ^a   Apseloff, Glen ^b   Kitzmiller, Joseph ^b   Harris, Stephen C ^a  

^a PURDUE PHARMA L P   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

analgesia; Buprenorphine pharmacokinetics; consistent and sustained delivery of buprenorphine; once weekly; pain management; patch; randomized trials; seven day transdermal delivery

Indexed keywords

BUPRENORPHINE; NALTREXONE;

ADULT; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL LABORATORY; CONSTIPATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSPEPSIA; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LOWER ABDOMINAL PAIN; MALE; NAUSEA; NORMAL HUMAN; PANIC; PATCH TEST; PHYSICAL EXAMINATION; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STEADY STATE; SUSTAINED RELEASE FORMULATION; TREATMENT DURATION; VENOUS BLOOD; VITAL SIGN; VOMITING;

ANALGESIA; BUPRENORPHINE PHARMACOKINETICS; CONSISTENT AND SUSTAINED DELIVERY OF BUPRENORPHINE; ONCE-WEEKLY; PAIN MANAGEMENT; PATCH; RANDOMIZED TRIALS; SEVEN-DAY TRANSDERMAL DELIVERY;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; HUMANS; MIDDLE AGED;

EID: 84880267368     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2012.06.014     Document Type: Article

References (53)

1. R.E. Johnson, P.J. Fudala, and R. Payne Buprenorphine: considerations for pain management J Pain Symptom Manage 29 2005 297 326 (Pubitemid 40386746)
2. J. Pergolizzi, A.M. Aloisi, and A. Dahan Current knowledge of buprenorphine and its unique pharmacological profile Pain Pract 10 2010 428 450
3. H.G. Kress Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine Eur J Pain 13 2009 219 230
4. A. Dahan, A. Yassen, and R. Romberg Buprenorphine induces ceiling in respiratory depression but not in analgesia Br J Anaesth 96 2006 627 632
5. A. Dahan, A. Yassen, and H. Bijl Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats Br J Anaesth 94 2005 825 834 (Pubitemid 40754001)
6. A. Umbricht, M.A. Huestis, E.J. Cone, and K.L. Preston Effects of high-dose intravenous buprenorphine in experienced opioid abusers J Clin Psychopharmacol 24 2004 479 487 (Pubitemid 39274202)
7. T. Christoph, B. Kögel, and K. Schiene Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain Eur J Pharmacol 507 2005 87 98 (Pubitemid 40126844)
8. R.B. Raffa, and Z. Ding Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonist Acute Pain 9 2007 145 152 (Pubitemid 47499155)
9. M.K. Greenwald, C.E. Johanson, and D.E. Moody Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers Neuropsychopharmacology 28 2003 2000 2009 (Pubitemid 37412109)
10. R. Likar Transdermal buprenorphine in the management of persistent pain-safety aspects Ther Clin Risk Manag 2 2006 115 125 (Pubitemid 43950070)
11. N. Griessinger, R. Sittl, and R. Likar Transdermal buprenorphine in clinical practice-a post-marketing surveillance study in 13,179 patients Curr Med Res Opin 21 2005 1147 1156 (Pubitemid 41140716)
12. R. Sittl, R. Likar, and B.P. Nautrup Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study Clin Ther 27 2005 225 237 (Pubitemid 40462016)
13. R. Sittl, N. Griessinger, and R. Likar Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial Clin Ther 25 2003 150 168 (Pubitemid 36206743)
14. K. Budd Buprenorphine and the transdermal system: the ideal match in pain management Int J Clin Pract Suppl 133 2003 9 14 (Pubitemid 36362950)
15. K. Budd, and B.J. Collett Old dog-new (ma)trix Br J Anaesth 90 2003 722 724
16. ® [full prescribing information] 2011 Purdue Pharma L.P. Stamford, CT
17. F. Bonnet, L. Eberhart, and E. Wennberg Fentanyl HCl iontophoretic transdermal system versus morphine IV-PCA for postoperative pain management: survey of healthcare provider opinion Curr Med Res Opin 25 2009 293 301
18. P. van Raders, M. Aubry, M. Friberg, C. Huygens, and T. Koch Nurses' views on ease of patient care in postoperative pain management Br J Nurs 16 2007 312 317
19. N.A. Hagen, M. Thirlwell, and J. Eisenhoffer Efficacy, safety, and steady-state pharmacokinetics of once-A-day controlled-release morphine (MS Contin XL) in cancer pain J Pain Symptom Manage 29 2005 80 90 (Pubitemid 40126227)
20. P. Pennington, S. Caminiti, J.R. Schein, D.J. Hewitt, and W.W. Nelson Patients' assessment of the convenience of fentanyl HCl iontophoretic transdermal system (ITS) versus morphine intravenous patient-controlled analgesia (IV PCA) in the management of postoperative pain after major surgery Pain Manag Nurs 10 2009 124 133
21. G. Hans, and D. Robert Transdermal buprenorphine-A critical appraisal of its role in pain management J Pain Res 2 2009 117 134
22. M.A. Russo, and J. Wasiak A clinical snapshot of transdermal buprenorphine in pain management Eur J Pain Suppl 1 2007 74 77 (Pubitemid 351597816)
23. R. Likar, and R. Sittl Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies Anesth Analg 100 2005 781 785 (Pubitemid 40300077)
24. K. Böhme Buprenorphine in a transdermal therapeutic system-A new option Clin Rheumatol 21 2002 S13 S16
25. N. Vadivelu, and R.L. Hines Management of chronic pain in the elderly: focus on transdermal buprenorphine Clin Interv Aging 3 2008 421 430
26. D. Steiner, C. Munera, M. Hale, S. Ripa, and C. Landau Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study J Pain 12 2011 1163 1173
27. D.J. Steiner, S. Sitar, and W. Wen Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study J Pain Symptom Manage 42 2011 903 917
28. A. Gordon, D. Callaghan, and D. Spink Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase Clin Ther 32 2010 844 860
29. A. Gordon, S. Rashiq, and D.E. Moulin Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain Pain Res Manag 15 2010 169 178
30. I.G. James, C.M. O'Brien, and C.J. McDonald A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain J Pain Symptom Manage 40 2010 266 278
31. C. Munera, M. Drehobl, N.E. Sessler, and C. Landau A randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritis J Opioid Manag 6 2010 193 202
32. C.J. Landau, W.D. Carr, and A.J. Razzetti Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-Analgesia study Clin Ther 29 2007 2179 2193 (Pubitemid 350148284)
33. A.M. Gallagher, J. Leighton-Scott, and T.P. van Staa Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: a retrospective cohort study Clin Ther 31 2009 1707 1715
34. R. Likar, E.M. Vadlau, and C. Breschan Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age Clin J Pain 24 2008 536 543
35. F. Louis Transdermal buprenorphine in pain management-experiences from clinical practice: five case studies Int J Clin Pract 60 2006 1330 1334 (Pubitemid 44363678)
36. C. Aurilio, M.C. Pace, and M.B. Passavanti Transdermal buprenorphine combined with spinal morphine and naropine for pain relief in chronic peripheral vasculopathy Minerva Anestesiol 71 2005 445 449 (Pubitemid 43932970)
37. M.P. Davis Buprenorphine in cancer pain Support Care Cancer 13 2005 878 887 (Pubitemid 41502247)
38. P. Schriek Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases Support Care Cancer 12 2004 882 884 (Pubitemid 40104785)
39. M. Kwarcinski, M. Cataldo, C. Munera, and B. Dain The use of immediate-release opioids as supplemental analgesia during the management of moderate to severe chronic pain with transdermal buprenorphine, a partial mu-opioid receptor agonist J Am Pharm Assoc 52 2012 284
40. J.J. Berti, and J.J. Lipsky Transcutaneous drug delivery: a practical review Mayo Clin Proc 70 1995 581 586
41. A. Cowan, E. Friderichs, W. Strasburger, and R.B. Raffa Basic pharmacology of buprenorphine K. Budd, R.B. Raffa, Buprenorphine-The unique opioid analgesic 2005 Georg Thieme Verlag Stuttgart, Germany 3 21
42. H.J. McQuay, and R.A. Moore Buprenorphine kinetics in humans A. Cowan, J.W. Lewis, Buprenorphine: Combatting drug abuse with a unique opioid 1995 Wiley-Liss New York 137 147
43. C.N. Chiang, and R.L. Hawks Pharmacokinetics of the combination tablet of buprenorphine and naloxone Drug Alcohol Depend 70 2003 S39 S47
44. D.S. Walter, and C.E. Inturrisi Absorption, distribution, metabolism, and excretion of buprenorphine in animals and humans A. Cowan, J.W. Lewis, Buprenorphine: Combatting drug abuse with a unique opioid 1995 Wiley-Liss New York 113 135
45. R.E. Bullingham, H.J. McQuay, and R.A. Moore Clinical pharmacokinetics of narcotic agonist-Antagonist drugs Clin Pharmacokinet 8 1983 332 343 (Pubitemid 13069550)
46. R.E. Bullingham, H.J. McQuay, E.J. Porter, M.C. Allen, and R.A. Moore Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis Br J Clin Pharmacol 13 1982 665 673 (Pubitemid 13139882)
47. G.R. Wilkinson, and D.G. Shand Commentary: a physiological approach to hepatic drug clearance Clin Pharmacol Ther 18 1975 377 390
48. H.A. Heit, and D.L. Gourlay Buprenorphine: new tricks with an old molecule for pain management Clin J Pain 24 2008 93 97 (Pubitemid 351156508)
49. R.P. Kapil, A. Cipriano, and G.H. Michels Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system Clin Drug Investig 329 2012 583 592
50. ® [full prescribing information] 2006 Reckitt Benckiser Pharmaceuticals, Inc. Richmond, VA
51. R.E. Bullingham, H.J. McQuay, D. Dwyer, M.C. Allen, and R.A. Moore Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis Br J Clin Pharmacol 12 1981 117 122 (Pubitemid 11034429)
52. S.L. Walsh, and T. Eissenberg The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic Drug Alcohol Depend 70 2003 S13 S27
53. ® [full prescribing information] 2005 Reckitt Benckiser Pharmaceuticals, Inc. Richmond, VA